Trade Illumina Inc - ILMN CFD
Add to favourite- Summary
- Historical Data
- Events
- Income Statement
- Balance Sheet
- Cash Flow
Spread | 0.26 | ||||||||
Long position overnight fee
Long position overnight fee
Go to platform | -0.026179% | ||||||||
Short position overnight fee
Short position overnight fee
Go to platform | 0.003957% | ||||||||
Overnight fee time | 21:00 (UTC) | ||||||||
Min traded quantity | 1 | ||||||||
Currency | USD | ||||||||
Margin | 5% | ||||||||
Stock exchange | United States of America | ||||||||
Commission on trade | 0% |
*Information provided by Capital.com
Illumina Inc ESG Risk Ratings
‘C’ score indicates satisfactory relative ESG performance and moderate degree of transparency in reporting material ESG data publicly.
Prev. Close* | 133.64 |
Open* | 135.54 |
1-Year Change* | -38.34% |
Day's Range* | 134.28 - 138.47 |
52 wk Range | 89.00-238.55 |
Average Volume (10 days) | 2.13M |
Average Volume (3 months) | 55.45M |
Market Cap | 21.32B |
P/E Ratio | -100.00K |
Shares Outstanding | 158.80M |
Revenue | 4.47B |
EPS | -7.12 |
Dividend (Yield %) | N/A |
Beta | 1.22 |
Next Earnings Date | Feb 8, 2024 |
All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
Date | Close | Change | Change (%) | Open | High | Low |
---|---|---|---|---|---|---|
Mar 27, 2024 | 138.47 | 3.96 | 2.94% | 134.51 | 138.55 | 133.83 |
Mar 26, 2024 | 133.64 | -0.91 | -0.68% | 134.55 | 135.54 | 133.19 |
Mar 25, 2024 | 134.00 | -2.94 | -2.15% | 136.94 | 137.07 | 132.56 |
Mar 22, 2024 | 137.13 | 1.50 | 1.11% | 135.63 | 137.42 | 133.54 |
Mar 21, 2024 | 137.34 | -2.40 | -1.72% | 139.74 | 143.83 | 136.20 |
Mar 20, 2024 | 133.00 | 0.70 | 0.53% | 132.30 | 133.17 | 129.14 |
Mar 19, 2024 | 133.02 | 4.33 | 3.36% | 128.69 | 135.55 | 127.65 |
Mar 18, 2024 | 130.02 | 1.80 | 1.40% | 128.22 | 131.29 | 125.71 |
Mar 15, 2024 | 127.55 | 1.08 | 0.85% | 126.47 | 128.32 | 125.84 |
Mar 14, 2024 | 128.00 | -2.96 | -2.26% | 130.96 | 133.02 | 126.11 |
Mar 13, 2024 | 132.62 | 1.21 | 0.92% | 131.41 | 135.40 | 131.38 |
Mar 12, 2024 | 132.56 | -4.74 | -3.45% | 137.30 | 138.77 | 132.54 |
Mar 11, 2024 | 138.98 | 3.39 | 2.50% | 135.59 | 139.91 | 134.92 |
Mar 8, 2024 | 135.31 | -1.59 | -1.16% | 136.90 | 139.73 | 133.96 |
Mar 7, 2024 | 135.83 | 0.23 | 0.17% | 135.60 | 138.46 | 135.12 |
Mar 6, 2024 | 134.99 | -0.54 | -0.40% | 135.53 | 136.88 | 133.12 |
Mar 5, 2024 | 134.50 | -0.97 | -0.72% | 135.47 | 137.23 | 134.23 |
Mar 4, 2024 | 137.55 | -2.00 | -1.43% | 139.55 | 140.50 | 135.45 |
Mar 1, 2024 | 140.33 | 2.48 | 1.80% | 137.85 | 142.55 | 134.95 |
Feb 29, 2024 | 139.62 | -3.75 | -2.62% | 143.37 | 145.89 | 139.62 |
Illumina Inc Events
Time (UTC) | Country | Event |
---|---|---|
Tuesday, April 23, 2024 | ||
Time (UTC) 10:59 | Country US
| Event Q1 2024 Illumina Inc Earnings Release Q1 2024 Illumina Inc Earnings ReleaseForecast -Previous - |
Friday, May 24, 2024 | ||
Time (UTC) 17:00 | Country US
| Event Illumina Inc Annual Shareholders Meeting Illumina Inc Annual Shareholders MeetingForecast -Previous - |
- Annual
- Quarterly
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Total revenue | 4584 | 4526 | 3239 | 3543 | 3333 |
Revenue | 4584 | 4526 | 3239 | 3543 | 3333 |
Cost of Revenue, Total | 1612 | 1372 | 1036 | 1076 | 1033 |
Gross Profit | 2972 | 3154 | 2203 | 2467 | 2300 |
Total Operating Expense | 8763 | 4649 | 2659 | 2504 | 2450 |
Selling/General/Admin. Expenses, Total | 1297 | 2092 | 941 | 835 | 794 |
Research & Development | 1321 | 1185 | 682 | 647 | 623 |
Unusual Expense (Income) | 4533 | -54 | 0 | ||
Operating Income | -4179 | -123 | 580 | 1039 | 883 |
Interest Income (Expense), Net Non-Operating | -121 | 919 | 237 | 75 | 8 |
Other, Net | -36 | 88 | 39 | 4 | 3 |
Net Income Before Taxes | -4336 | 884 | 856 | 1118 | 894 |
Net Income After Taxes | -4404 | 762 | 656 | 990 | 793 |
Minority Interest | 0 | 12 | 44 | ||
Net Income Before Extra. Items | -4404 | 762 | 656 | 1002 | 837 |
Net Income | -4404 | 762 | 656 | 1002 | 826 |
Income Available to Common Excl. Extra. Items | -4404 | 762 | 656 | 1002 | 837 |
Income Available to Common Incl. Extra. Items | -4404 | 762 | 656 | 1002 | 826 |
Diluted Net Income | -4404 | 762 | 656 | 1002 | 826 |
Diluted Weighted Average Shares | 157 | 151 | 148 | 149 | 149 |
Diluted EPS Excluding Extraordinary Items | -28.051 | 5.04636 | 4.43243 | 6.72483 | 5.61745 |
Dividends per Share - Common Stock Primary Issue | |||||
Diluted Normalized EPS | -9.28376 | 5.04636 | 4.43243 | 6.40391 | 5.61745 |
Total Extraordinary Items | -11 |
Jul 2023 | Apr 2023 | Jan 2023 | Oct 2022 | Jul 2022 | |
---|---|---|---|---|---|
Total revenue | 1176 | 1087 | 1083 | 1115 | 1162 |
Revenue | 1176 | 1087 | 1083 | 1115 | 1162 |
Cost of Revenue, Total | 444 | 432 | 411 | 398 | 395 |
Gross Profit | 732 | 655 | 672 | 717 | 767 |
Total Operating Expense | 1264 | 1151 | 1210 | 4772 | 1741 |
Selling/General/Admin. Expenses, Total | 432 | 377 | 432 | 146 | 410 |
Research & Development | 346 | 341 | 346 | 325 | 327 |
Operating Income | -88 | -64 | -127 | -3657 | -579 |
Interest Income (Expense), Net Non-Operating | -3 | -17 | -31 | -5 | -36 |
Other, Net | 2 | 3 | -10 | -10 | -22 |
Net Income Before Taxes | -89 | -78 | -168 | -3672 | -637 |
Net Income After Taxes | -234 | 3 | -139 | -3816 | -535 |
Net Income Before Extra. Items | -234 | 3 | -139 | -3816 | -535 |
Net Income | -234 | 3 | -139 | -3816 | -535 |
Income Available to Common Excl. Extra. Items | -234 | 3 | -139 | -3816 | -535 |
Income Available to Common Incl. Extra. Items | -234 | 3 | -139 | -3816 | -535 |
Diluted Net Income | -234 | 3 | -139 | -3816 | -535 |
Diluted Weighted Average Shares | 158 | 158 | 157 | 157 | 157 |
Diluted EPS Excluding Extraordinary Items | -1.48101 | 0.01899 | -0.88535 | -24.3057 | -3.40764 |
Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
Diluted Normalized EPS | -1.29589 | 0.0231 | -0.79841 | -8.14682 | -0.88631 |
Unusual Expense (Income) | 42 | 1 | 21 | 3903 | 609 |
- Annual
- Quarterly
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Total Current Assets | 3561 | 2713 | 4483 | 4451 | 4490 |
Cash and Short Term Investments | 2037 | 1339 | 3472 | 3414 | 3512 |
Cash & Equivalents | 2011 | 1232 | 1810 | 2042 | 1144 |
Short Term Investments | 26 | 107 | 1662 | 1372 | 2368 |
Total Receivables, Net | 688 | 648 | 487 | 573 | 514 |
Accounts Receivable - Trade, Net | 688 | 648 | 487 | 573 | 514 |
Total Inventory | 568 | 431 | 372 | 359 | 386 |
Prepaid Expenses | 268 | 295 | 152 | 105 | 78 |
Total Assets | 12252 | 15217 | 7585 | 7316 | 6959 |
Property/Plant/Equipment, Total - Net | 1744 | 1696 | 1454 | 1444 | 1075 |
Property/Plant/Equipment, Total - Gross | 2706 | 2492 | 2132 | 2012 | 1596 |
Accumulated Depreciation, Total | -962 | -796 | -678 | -568 | -521 |
Goodwill, Net | 3239 | 7113 | 897 | 824 | 831 |
Intangibles, Net | 3285 | 3250 | 142 | 145 | 185 |
Other Long Term Assets, Total | 212 | 445 | 609 | 452 | 378 |
Total Current Liabilities | 2773 | 1093 | 1244 | 665 | 1804 |
Accounts Payable | 293 | 332 | 192 | 149 | 184 |
Accrued Expenses | 890 | 429 | 287 | 263 | 256 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Port. of LT Debt/Capital Leases | 1248 | 0 | 511 | 0 | 1107 |
Other Current Liabilities, Total | 342 | 332 | 254 | 253 | 257 |
Total Liabilities | 5653 | 4477 | 2891 | 2703 | 3201 |
Total Long Term Debt | 1487 | 1695 | 673 | 1141 | 890 |
Long Term Debt | 1487 | 1695 | 673 | 1141 | 890 |
Minority Interest | 0 | 148 | |||
Other Liabilities, Total | 1393 | 1689 | 974 | 897 | 359 |
Total Equity | 6599 | 10740 | 4694 | 4613 | 3758 |
Common Stock | 2 | 2 | 2 | 2 | 2 |
Additional Paid-In Capital | 9207 | 8938 | 3815 | 3560 | 3290 |
Retained Earnings (Accumulated Deficit) | 1142 | 5485 | 4723 | 4067 | 3083 |
Treasury Stock - Common | -3755 | -3702 | -3848 | -3021 | -2616 |
Unrealized Gain (Loss) | 1 | 4 | -2 | ||
Other Equity, Total | 3 | 17 | 1 | 1 | 1 |
Total Liabilities & Shareholders’ Equity | 12252 | 15217 | 7585 | 7316 | 6959 |
Total Common Shares Outstanding | 158 | 157 | 146 | 147 | 147 |
Preferred Stock - Non Redeemable, Net | 0 | 0 | 0 | 0 | |
Long Term Investments | 211 |
Oct 2023 | Jul 2023 | Apr 2023 | Jan 2023 | Oct 2022 | |
---|---|---|---|---|---|
Total Current Assets | 2506 | 3223 | 3172 | 3561 | 2487 |
Cash and Short Term Investments | 933 | 1559 | 1518 | 2037 | 1041 |
Cash & Equivalents | 927 | 1553 | 1494 | 2011 | 1000 |
Short Term Investments | 6 | 6 | 24 | 26 | 41 |
Total Receivables, Net | 709 | 758 | 682 | 688 | 645 |
Accounts Receivable - Trade, Net | 709 | 758 | 682 | 688 | 645 |
Total Inventory | 615 | 617 | 586 | 568 | 559 |
Prepaid Expenses | 249 | 289 | 386 | 268 | 242 |
Total Assets | 10122 | 11774 | 11811 | 12252 | 11256 |
Property/Plant/Equipment, Total - Net | 1621 | 1707 | 1740 | 1744 | 1748 |
Goodwill, Net | 2527 | 3239 | 3239 | 3239 | 3238 |
Intangibles, Net | 3029 | 3188 | 3237 | 3285 | 3335 |
Other Long Term Assets, Total | 246 | 212 | 223 | 212 | 222 |
Total Current Liabilities | 1482 | 2303 | 2230 | 2773 | 2669 |
Accounts Payable | 240 | 244 | 242 | 293 | 281 |
Accrued Expenses | 935 | 975 | 907 | 890 | 836 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Port. of LT Debt/Capital Leases | 0 | 750 | 749 | 1248 | 1246 |
Other Current Liabilities, Total | 307 | 334 | 332 | 342 | 306 |
Total Liabilities | 4224 | 5219 | 5118 | 5653 | 4525 |
Total Long Term Debt | 1489 | 1488 | 1487 | 1487 | 495 |
Long Term Debt | 1489 | 1488 | 1487 | 1487 | 495 |
Other Liabilities, Total | 1253 | 1428 | 1401 | 1393 | 1361 |
Total Equity | 5898 | 6555 | 6693 | 6599 | 6731 |
Common Stock | 2 | 2 | 2 | 2 | 2 |
Additional Paid-In Capital | 9487 | 9397 | 9311 | 9207 | 9129 |
Retained Earnings (Accumulated Deficit) | 157 | 911 | 1145 | 1142 | 1281 |
Treasury Stock - Common | -3769 | -3767 | -3764 | -3755 | -3720 |
Other Equity, Total | 21 | 12 | -1 | 3 | 39 |
Total Liabilities & Shareholders’ Equity | 10122 | 11774 | 11811 | 12252 | 11256 |
Total Common Shares Outstanding | 158 | 158 | 158 | 158 | 157 |
Preferred Stock - Non Redeemable, Net | 0 | ||||
Long Term Investments | 193 | 205 | 200 | 211 | 226 |
- Annual
- Quarterly
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Net income/Starting Line | -4404 | 762 | 656 | 990 | 782 |
Cash From Operating Activities | 392 | 545 | 1080 | 1051 | 1142 |
Cash From Operating Activities | 215 | 176 | 156 | 151 | 140 |
Amortization | 179 | 75 | 31 | 37 | 39 |
Deferred Taxes | -23 | -76 | 117 | 11 | -18 |
Non-Cash Items | 4221 | -240 | 47 | 56 | 217 |
Cash Taxes Paid | 122 | 233 | 119 | 164 | 99 |
Changes in Working Capital | 204 | -152 | 73 | -194 | -18 |
Cash From Investing Activities | -591 | -1069 | -554 | 745 | -1813 |
Capital Expenditures | -466 | -208 | -189 | -209 | -296 |
Other Investing Cash Flow Items, Total | -125 | -861 | -365 | 954 | -1517 |
Cash From Financing Activities | 1000 | -51 | -766 | -897 | 594 |
Financing Cash Flow Items | -54 | -582 | -91 | -82 | 18 |
Issuance (Retirement) of Stock, Net | 63 | 60 | -675 | -265 | -155 |
Issuance (Retirement) of Debt, Net | 991 | 471 | 0 | -550 | 731 |
Foreign Exchange Effects | -22 | -3 | 8 | -1 | -4 |
Net Change in Cash | 779 | -578 | -232 | 898 | -81 |
Apr 2023 | Jan 2023 | Oct 2022 | Jul 2022 | Apr 2022 | |
---|---|---|---|---|---|
Net income/Starting Line | 3 | -4404 | -4265 | -449 | 86 |
Cash From Operating Activities | 10 | 392 | 245 | 297 | 172 |
Cash From Operating Activities | 57 | 215 | 158 | 102 | 50 |
Amortization | 50 | 179 | 130 | 83 | 41 |
Deferred Taxes | -17 | -23 | -40 | -34 | -21 |
Non-Cash Items | 112 | 4221 | 4044 | 255 | 81 |
Changes in Working Capital | -195 | 204 | 218 | 340 | -65 |
Cash From Investing Activities | -56 | -591 | -489 | -239 | -74 |
Capital Expenditures | -53 | -466 | -378 | -132 | -61 |
Other Investing Cash Flow Items, Total | -3 | -125 | -111 | -107 | -13 |
Cash From Financing Activities | -473 | 1000 | 44 | 16 | 21 |
Financing Cash Flow Items | -10 | -54 | -19 | -17 | -12 |
Issuance (Retirement) of Stock, Net | 37 | 63 | 63 | 33 | 33 |
Issuance (Retirement) of Debt, Net | -500 | 991 | 0 | 0 | 0 |
Foreign Exchange Effects | 2 | -22 | -32 | -17 | 0 |
Net Change in Cash | -517 | 779 | -232 | 57 | 119 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
Illumina Company profile
What is Illumina?
Illumina Inc (ILMN) is a San Diego-based U.S. company engaged in the development and marketing of genetic analysis solutions and life science services. Over the past decade it has become a global leader in genomics. Illumina offers a broad portfolio of instruments including NovaSeq Sequencing Systems,HiSeq Sequencing Systems, HiScan Array Scanner and others.
Illumina explains that its aim is “to apply innovative technologies to the analysis of genetic variation and function, making studies possible that were not even imaginable just a few years ago”. The company says it delivers innovative, flexible, and scalable solutions to meet the needs of its customers.These customers include leading genome research centres and a variety of other academic, governmental, pharmaceutical and biotechnology institutions around the world.
In 2017 Forbes ranked Illumina no.18 in its annual list of the world’s most innovative companies. The company was also ranked no.34 in its league table of America's best midsize employers, and no.175 in Forbes’ list of growth champions. As of 6 April 2018, Illumina Inc had a market capitalisation of some $34.14 billion.
Who are the key people at Illumina?
Francis de Souza, who has been President & CEO of Illumina Inc since 2016, is responsible for directing all aspects of company strategy, planning and operations. Other key figures at the company include: Garret Hampton (Executive Vice President, Clinical Genomics); Omead Ostadan (Executive Vice President, Products & Operations); and Marc Stapley (Executive Vice President, Strategy & Corporate Development).
What is the modern history of Illumina?
The company was foundedin 1998 by David R. Walt, John R. Stuelpnagel, Anthony W. Czarnik, Lawrence A. Bock and Mark S. Chee. It acquired Spyder Instruments the following year, and completed its initial public offering in 2000. The acquisition of Solexa Inc followed in 2007, and Epicentre Biotechnologies was acquired in 2011. Roche made an unsolicited bid to buy Illumina for around $5.7 billion in 2012, but both this and a subsequent higher offer were rejected. In 2015, Illumina spun off the blood testing company Grail.
What are the latest developments at Illumina?
In its financial results for fiscal year 2017, Illumnia Inc reported revenue of $2.75 billion, a 15% increase from $2.40 billion in fiscal year 2016.GAAP net income attributable to Illumina stockholders was $726 million, or $4.92 per diluted share, against $463 million or $3.07 per diluted share in 2016.For fiscal year 2018, the company forecast 13-14% revenue growth, and GAAP earnings per diluted share attributable to Illumina stockholders of $4.14-$4.24.
Long-term investors in Illumina saw the value of their holdings increase significantly between 2013 and 2018. From $54 in January 2013, the Illumina share price climbed to $100 in December 2013, $150 in February 2014, and $200 in May 2015. The shares slipped in the second half of 2015, but by March 2018 the stock had recovered to a new high of $253. To find out how the shares are doing right now, follow Capital.com. Our ILMN chart puts all the information at your fingertips.
Where does Illumina operate?
Headquartered in San Diego, California,Illumina's regional subdivisions operate in the United States, Brazil, the United Kingdom, the Netherlands, Singapore, China, Japan and Australia.The company employs over 5,500 people.
Where is Illumina traded?
The company shares are traded on the NASDAQ stock exchange and are constituents of the S&P 500 index. Check out Capital.com for the latest ILMN chart. We’ll keep you up to date and in the picture.
Industry: | Advanced Medical Equipment & Technology (NEC) |
5200 Illumina Way
SAN DIEGO
CALIFORNIA 92122
US
Income Statement
- Annual
- Quarterly
News
A way forward: a roundup of recent central bank decisions
Five of the world’s most significant central banks delivered policy this week. We review the decisions and discuss their impact on the markets.
12:47, 22 March 2024Bank of Japan Preview: will the BOJ end negative interest rates?
The Bank of Japan meets on Tuesday 19th of March. We preview what to expect from the BOJ decision and how it might impact the USD/JPY and Nikkei 225.
08:44, 18 March 2024Higher CPI leaves traders unfazed as US equities continue to build momentum
The latest US CPI reading hasn’t gone how the Federal would have hoped. Consumer prices came in higher than expected in February for the third month in a row.
12:42, 15 March 2024Four reasons why Bitcoin is surging to record highs
Bitcoin has surged to record highs. We discuss the four factors pushing Bitcoin higher and analyse the technicals of the cryptocurrency’s technicals.
10:18, 14 March 2024China’s National People’s Congress: The markets have again been left wanting more
China’s National People’s Congress (NPC) is underway, and the markets have so far been disappointed by what’s been delivered by the country’s central government. We look at some of the significant takeaways from the event, discuss China’s current economic conditions, and analyse the China A50.
08:23, 8 March 2024Central Banks: which one will cut first?
Central banks dominate the calendar in March and markets try to anticipate which one will be the first one to cut
13:14, 6 March 2024Nvidia (NVDA) confronts high expectations for Q4 results
Nvidia is arguably the hottest company on the planet. The company reports its Q4 results after the closing bell on Wednesday, the 21st of February. We preview what to expect from Nvidia’s earnings and analyse the technicals of its stock price.
12:13, 20 February 2024People also watch
Still looking for a broker you can trust?
Join the 580.000+ traders worldwide that chose to trade with Capital.com